Please login to the form below

Not currently logged in
Email:
Password:

NicOx strengthens R&D organisation through new hires

NicOx has hired Dr Pascal Pfister as CSO

French biopharmaceutical company NicOx has hired Dr Pascal Pfister as Chief Scientific Officer (CSO).

Dr Pfister will report to Michele Garufi, Chairman and CEO, and will have overall responsibility for NicOx's R&D activities, notably the research, regulatory affairs, clinical development and drug development departments.

Pfister brings extensive experience and leadership to NicOx from his 19 year career at Novartis and Sandoz. Pfister's previous management career includes 19 years at Novartis & Sandoz Pharmaceuticals in France, Switzerland and in the US, where he has occupied positions of growing responsibility in a range of therapeutic fields, including the inflammatory and cardiometabolic disease areas.

Pfisterís most recent position was vice-president of global therapeutic area head for respiratory and dermatology, clinical development and medical affairs, where he was responsible for managing a large team across the EU, the UK and the US.

NicOx has also further strengthened its R&D team through the appointment of Dr Jacques Djian as cardiometabolic leader, who will advise and manage NicOx' R&D in this area.

Dr Djian comes to NicOx with 16 years of experience in the pharmaceutical industry and was previously the senior scientific consultant for cardiovascular and metabolic disease issues at Novartis.

Djian has also worked for Wyeth Research as global senior director of the cardiovascular area and at Sanofi, where he was scientific director of clinical development.

4th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics